| Trial ID: | L0277 |
| Source ID: | NCT02918929
|
| Associated Drug: |
EDP-305
|
| Title: |
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Presumptive NAFLD
|
| Interventions: |
Drug: EDP 305|Drug: Placebo
|
| Outcome Measures: |
Safety data including but not limited to adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).|Cmax|AUC
|
| Sponsor/Collaborators: |
Enanta Pharmaceuticals|Pharmaceutical Research Associates
|
| Gender: |
All
|
| Age: |
18 Years to 55 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
146
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
September 2016
|
| Completion Date: |
June 2017
|
| Results First Posted: |
--
|
| Last Update Posted: |
August 21, 2017
|
| Locations: |
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02918929
|
